Our commitment to corporate governance underpins the trust that our investors, employees and institutions have in us. We maintain our efforts to build confidence as we continue to grow.
Management Board
Valneva’s Management Board is a highly dedicated international team, with diverse backgrounds, experience, expertise and skills.
Thomas Lingelbach was CEO of Intercell and founding CEO of Valneva.
He is an established vaccine industry leader with breadth of experience. Prior to Valneva Thomas had senior & executive management roles with Intercell, Novartis and Chiron.
During his 30 years in vaccines, he held a variety of positions from product development to commercialization with a strong emphasis on technical development & operations.
In different capacities, he contributed to the successful development and licensure of more than ten vaccines.
Thomas Lingelbach holds an engineering degree, specialized in bioprocess engineering and complemented his education with a business administration program.
He is a German national, born in 1963.
Franck Grimaud was co-founder, President & CEO of Vivalis and co-led its merger with Intercell to create Valneva.
He has a long-standing and proven track record in strategic, corporate and business development management, with more than 23 years in the biotech industry.
Prior to creating and successfully building Vivalis as a French public biotech company, he was responsible for the creation of the Asian subsidiaries of Groupe Grimaud, a leader in animal genetic selection and currently Valneva’s largest shareholder.
Franck Grimaud holds an MBA.
He is a French national, born in 1966.
Peter joined Valneva as CFO in early 2022.
He has over 20 years of experience in the strategic and financial leadership of life science and technology companies.
Before joining Valneva, he served as CFO of Nasdaq-listed Swiss diagnostics company Quotient. He also served as Group CFO of Zaluvida AG and as Group CFO of Stallergenes Greer Plc, where he led a complex merger project to combine a French and U.S. company.
Prior to this, Peter held senior finance roles at Eli Lilly, Merck Serono and Logitech.
He is a Swiss Certified Accountant and holds an executive MBA.
Peter is a Swiss national, born in 1969.
Dr. Juan Carlos Jaramillo joined Valneva in October 2020.
He is an experienced R&D leader with a broad expertise in medical affairs, clinical development including vaccines, as well as market access and pricing.
During his more than 20 years in the pharmaceutical industry and prior to joining Valneva, he held senior management roles with Daiichi Sankyo, Grünenthal and GlaxoSmithKline.
Due to his diverse pharma exposure, he has an in-depth business understanding and a strong track record of success across a wide range of settings, therapeutic areas and geographies.
Juan Carlos Jaramillo is a Medical Doctor.
He was born in 1970 in Colombia, raised and educated in the US and holds U.S. citizenship.
Frederic Jacotot joined Valneva as VP Legal & IP and General Counsel shortly after the creation of the Company, and joined the Management Board in April 2017.
He is an established legal expert in the pharmaceutical industry.
During his 30 years in the business he has held a variety of positions with increasing responsibilities and, prior to Valneva, served as Division Counsel at Abbott.
Frederic holds a Master’s degree in business law from Paris 1 University.
He is a French national, born in 1964.
Supervisory Board
As part of Valneva’s corporate governance system, the Supervisory Board participates actively in reviewing the Company’s strategic options and setting direction together with the Management Board.
Chairman of Valneva’s Supervisory Board, Representative of the Company's largest shareholder, President and CEO of Groupe Grimaud.
Member of the Supervisory Board & Chair - Audit Committee, Former CFO for Chiron and CEO of Maxygen.
Member of the Supervisory Board, Managing Director of SMAG Consulting, Supervisory Board member of Nanobiotix SA, Board member of Sartorius Stedim Biotech SA, Former Vice President at Sanofi Pasteur MSD.
Member of the Supervisory Board, Founder and Managing Partner of Potrero Hill Advisors, Member of the Board of Directors and Audit Committee Chair of Catalyst Biosciences (NASDAQ:CBIO).
Member of the Supervisory Board, Former General Manager of Novartis Vaccines and Diagnostics in Basel (now a GlaxoSmithKline company) and GSK / Novartis vaccines integration lead. Previously held various commercial and medical roles at GSK, Organon and Byk Gulden.
Scientific Advisory Board
Valneva announced the formation of a Scientific Advisory Board (SAB) as part of the evolution of its governance structure in July 2019.
Member of Board of Trustees International Vaccine Institute IVI, member GHIT scientific selection committee, Advisor Bill & Melinda Gates Foundation, former Head/Senior Vice President Vaccine Development at GSK, Novartis and Takeda
President and CEO of Biologics Consulting, Temporary Advisor to the World Health Organization; Former Director of the US FDA Office of Vaccines Research and Review; Former FDA Liaison to the Centers for Disease Control’s Advisory Committee on Immunization Practices
Professor of Immunobiology at the Max Perutz Labs of the University of Vienna; President of the European Macrophage and Dendritic Cell Society (EMDS), Member of editorial boards for the scientific journals Molecular Cell Biology and Journal of Biochemistry.
Professor of International Health at the Johns Hopkins Bloomberg School of Public Health, Principal Investigator at the Center for Immunization Research
Co-founder of Intercell and member of Valneva’s SAB. He is also holding an observer seat on Valneva’s Supervisory Board. Furthermore, he is serving in the SAB of the Paul Ehrlich Institute, Frankfurt and in the Board of Trustees of the Institute of Science and Technology, Austria. He is Vice-President off duty at the Karolinska Intitutet, Stockholm.
